Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Morganroth

Showing results (41-50 of 214) with videos related to

Pageof 22
Sort By:
The American Journal of Digestive Diseases|July 1, 1970
Sensitivity to atypical mycobacterial antigens in patients with Crohn's diseaseJ Morganroth, D W Watson
The American Journal of Cardiology|August 1, 1986
Effectiveness of low-dose nadolol for ventricular arrhythmiasJ Morganroth, K L Duchin
The American Journal of Cardiology|February 20, 1990
Overview: moricizine--can it meet the challenge?J Morganroth, J T Bigger
Journal of the American College of Cardiology|February 1, 1987
Second generation antiarrhythmic agents: have we reached antiarrhythmic Nirvana?L N Horowitz, J Morganroth
The American Journal of Cardiology|January 15, 1989
Prevalence and characteristics of proarrhythmia from moricizine (Ethmozine)J Morganroth, C M Pratt
Annals of Internal Medicine|November 1, 1977
Familial type III hyperlipoproteinemiaR I Levy, J Morganroth
Pharmacology & Therapeutics|January 1, 1980
Antiarrhythmic agents and their use in therapyL S Dreifus, J Morganroth
Annals of the New York Academy of Sciences|January 1, 1977
The athlete's heart syndrome: a new perspectiveJ Morganroth, B J Maron
Comprehensive Therapy|April 1, 1987
Antiarrhythmic agents for chronic ventricular arrhythmiasP F Nestico, J Morganroth
Comprehensive Therapy|September 1, 1984
Ventricular arrhythmias: current conceptsP F Nestico, J Morganroth
Pageof 22

Showing results (41-50 of 214) with videos related to

Sort By:
Pageof 22
The American Journal of Digestive Diseases|July 1, 1970
Sensitivity to atypical mycobacterial antigens in patients with Crohn's diseaseJ Morganroth, D W Watson
The American Journal of Cardiology|August 1, 1986
Effectiveness of low-dose nadolol for ventricular arrhythmiasJ Morganroth, K L Duchin
The American Journal of Cardiology|February 20, 1990
Overview: moricizine--can it meet the challenge?J Morganroth, J T Bigger
Journal of the American College of Cardiology|February 1, 1987
Second generation antiarrhythmic agents: have we reached antiarrhythmic Nirvana?L N Horowitz, J Morganroth
The American Journal of Cardiology|January 15, 1989
Prevalence and characteristics of proarrhythmia from moricizine (Ethmozine)J Morganroth, C M Pratt
Annals of Internal Medicine|November 1, 1977
Familial type III hyperlipoproteinemiaR I Levy, J Morganroth
Pharmacology & Therapeutics|January 1, 1980
Antiarrhythmic agents and their use in therapyL S Dreifus, J Morganroth
Annals of the New York Academy of Sciences|January 1, 1977
The athlete's heart syndrome: a new perspectiveJ Morganroth, B J Maron
Comprehensive Therapy|April 1, 1987
Antiarrhythmic agents for chronic ventricular arrhythmiasP F Nestico, J Morganroth
Comprehensive Therapy|September 1, 1984
Ventricular arrhythmias: current conceptsP F Nestico, J Morganroth
Pageof 22